Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100). (Q36933302)
Jump to navigation
Jump to search
scientific article published on 27 August 2011
Language | Label | Description | Also known as |
---|---|---|---|
English | Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100). |
scientific article published on 27 August 2011 |
Statements
1 reference
Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100). (English)
1 reference
David Cella
1 reference
Kathy Miller
1 reference
Molin Wang
1 reference
Lynne Wagner
1 reference
27 August 2011
1 reference
1 reference
855-861
1 reference
Identifiers
1 reference
1 reference
1 reference